anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Dental assemblies and related methods of making are provided. The dental assemblies include a dental article with a bonding surface an adhesive having both a compressible material and at least one hardenable dental composition extending across the bonding surface. The compressible material is coupled to the dental article by a first quantity of hardened dental composition extending at least partially through the compressible material and contacting the bonding surface. The hardened dental composition extends over less than the entire bonding surface. Adjacent portions of the compressible material contain a second quantity of unhardened dental composition, preserving flexibility of the compressible material. Advantageously, this configuration was found to enhance bond reliability and facilitate manufacturing.
FIELD: organic chemistry, chemical technology, pharmacy. SUBSTANCE: invention relates to method of preparing pharmaceutically acceptable clavulanic acid salt of the formula (I)   by interaction of clavulanic acid or its salt, in part, amine salt with cation source which is able to form a pharmaceutically acceptable clavulanic acid salt, in part, potassium salt in isobutanol (2-methyl-1- propanol) as a solvent in the presence of water. Pharmaceutically acceptable clavulanic acid salt has up to 5 wt. -% or less of isobutanol and water as microimpurities. Mixture eliciting antibiotic action has amoxicillin and clavulanic acid potassium salt containing isobutanol and water. Method of preparing clavulanic acid alkaline metal of the formula (I) from clavulanic acid amine salt by addition of alkaline metal in the presence of isobutanol as a solvent and 2.0-5.0% of water. EFFECT: improved and simplified method of preparing. 19 cl, 9 ex
FIELD: production of medicinal. SUBSTANCE: active liquid ingredient is mixed with macroporous ionite at mass ratio 1: /1: 20/. Then mixture is dried by hot air to remove solvent. Thus spheric granules are produced. Granulation time is 15-60 min, method has three technological stages. EFFECT: accelerates and simplifies the method.
Disclosed herein is a bispecific version of a T cell receptor mimetic (TCRm) mAb reactive with human immune effector cell antigen and WT1 peptide/HLA-a epitope. The antibody selectively binds to leukemia and solid tumor cells expressing WT1 and HLA-A and activated resting human T cells that release interferon- (IFN-. gamma.) and kill target cancer cells in vitro. Importantly, the antibodies mediate autologous T cell proliferation and targeted potent cytotoxicity against fresh ovarian cancer cells. 3 different WT1/HLA-A2 expressing human cancers (including diffuse Ph + Acute Lymphocytic Leukemia (ALL), diffuse acute myeloid leukemia or peritoneal mesothelioma) were used in NOD SCID SCID γ c * The in vivo therapeutic activity of the antibodies was demonstrated in (NSG) mice. Mice receiving the antibodies and T cells also showed longer survival and delayed acroparalysis in both leukemia xenograft models. Also provided are methods of stimulating a primary T cell response comprising stimulating cytotoxic T cells against a first tumor antigen and a secondary T cell response comprising stimulating cytotoxic T cells against a first tumor antigen using the bispecific antibodies described hereinAn antigen and/or effector T cells and/or memory T cells directed against a second tumor antigen.
The HairDx Test reports genetic variants associated with the development of FPHL. The variants are detected from a saliva sample collected at home. The HairDx Test report is designed to help individuals understand the meaning of their results and encourage a conversation with a healthcare professional. The information provided by the HairDx Test report is not intended to start, stop or change any course of treatment. The purpose of this study is to collect DNA samples from subjects. The DNA samples will be used for the analytical validation of the HairDx Test. The results of this study will not be shared with the subjects.
The rate of caesarean section (CS) is increasing worldwide. Defects in uterine healing have a major gynaecological and obstetric impact (uterine rupture, caesarean scar defect, caesarean scar pregnancy, placenta accreta spectrum). The complex process of cellular uterine healing after surgery, and specifically after CS, remains poorly understood in contrast to skin wound healing. This literature review on uterine wound healing was mainly based on histological observations, particularly after CS. The primary objective of the review was to examine the effects of CS on uterine tissue at the cellular level, based on histological observations. The secondary objectives were to describe the biomechanical characteristics and the therapies used to improve scar tissue after CS. This review was performed using PRISMA criteria, and PubMed was the data source. The study included all clinical and animal model studies with CS and histological analysis of the uterine scar area (macroscopic, microscopic, immunohistochemical and biomechanical). Twenty studies were included: 10 human and 10 animal models. In total, 533 female humans and 511 female animals were included. Review articles, meeting abstracts, case series, case reports, and abstracts without access to full-text were excluded. The search was limited to studies published in English. No correlation was found between cutaneous and uterine healing. The histology of uterine scars is characterized by disorganized smooth muscle, fibrosis with collagen fibres and fewer endometrial glands. As for skin healing, the initial inflammation phase and mediation of some growth factors (particularly connective tissue growth factor, vascular endothelial growth factor, platelet-derived growth factor, tumour necrosis factor α and tumour necrosis factor β) seem to be essential. This initial phase has an impact on the subsequent phases of proliferation and maturation. Collagen appears to play a key role in the initial granulation tissue to replace the loss of substance. Subsequent maturation of the scar tissue is essential, with a decrease in collagen and smooth muscle restoration. Unlike skin, the glandular structure of uterine tissue could be responsible for the relatively high incidence of healing defects. Uterine scar defects after CS are characterized by an atrophic disorganized endometrium with atypia and a fibroblastic highly collagenic stromal reaction. Concerning immunohistochemistry, one study found a decrease in tumour necrosis factor β in uterine scar defects. No correlation was found between biomechanical characteristics (particularly uterine strength) and the presence of a collagenous scar after CS. Based on the findings of this review, an illustration of current understanding about uterine healing is provided. There is currently no validated prevention of caesarean scar defects. Various treatments to improve uterine healing after CS have been tested, and appeared to have good efficacy in animal studies: alpha lipoic acid, growth factors, collagen scaffolds and mesenchymal stem cells. Further prospective studies are needed.
The present invention relates to sealed and heat-treated ginger having excellent antioxidant and antidiabetic activity and a manufacturing method thereof and, more specifically, to sealed and heat-treated ginger having excellent antioxidant and antidiabetic activity which is manufactured by inserting underground portions of washed and water-removed ginger into a container to seal the underground portions and heating the underground portions at a high temperature of 80-90°C for 4-8 days; and a manufacturing method thereof. The manufacturing method of ginger manufactures ginger by inserting ginger into a sealed container and then heating the ginger at 80-90°C for 4-8 days to manufacture ginger without loss of water and volatile components, functionality degradation, and loss of effective components in comparison to conventional hot air drying and high temperature steaming (hot water immersion) processes. Sealed and heat-treated ginger manufactured by the same exhibits stronger antioxidant and antidiabetic activity than raw ginger. Specifically, since the ginger is manufactured under sealed conditions, water loss is eliminated to be applied to food without a separate hydration process to provide efficiency. Also, an extract of the sealed and heat-treated ginger can be processed in various forms such as extract, powder, tablet, and pill to be prepared in forms which can be taken at any time. Therefore, the present invention is very useful in the pharmaceutical industry, food industry, and cosmetic industry.
Sterilized durable medicinal solutions in hermetically sealed vessels, particularly ampoules, are degassed and prepared by applying a vacuum to the solution, subjecting the solution while still under vacuum to oscillations of a frequency between 15 and 60 KHz, so that no chemical reactions take place, saturating the solution with an inert gas such as nitrogen, sealing the vessel or ampoules, and heating the sealed vessels containing the solution to sterilizing temperature.  Preferably the solution is repeatedly subjected to vacuum and said oscillations before being sealed in the vessel.  The oscillations may be produced by a magnetostrictive transmitter or by a quartz crystal the emitted energy being up to 2 kW, the emitted energy preferably passing through a bath of liquid such as water or kerosene directly on to the vessel which contains the solution to be treated.  Examples relate to the degassing of solutions of morphinum hydrochloricum, adrenalin, and vitamin E dissolved in olive oil. After being degassed these solutions can be sterilized at temperatures of 110 to 115 DEG C. during a period of 15 minutes.ALSO:Sterilzed durable medicinal solutions free from dissolved carbon dioxide and oxygen in hermetically sealed vessels, particularly ampoules, are prepared by applying a vacuum to the solution, subjecting the solution while still under vacuum to oscillations of a frequency between 15 and 60 KHz, so that no chemical reactions take place, saturating the solution with an inert gas such as nitrogen, sealing the vessel or ampoules, and heating the sealed vessels containing the solution to sterilizing temperature. Preferably the solution is repeatedly subjected to vacuum and said oscillations before being sealed in the vessel. The oscillations may be produced by a magnetostrictive transmitter or by a quartz crystal, the emitted energy being up to 2 kW, the emitted energy preferably passing through a bath of liquid such as water or kerosene directly on to the vessel which contains the solution to be treated.  Examples relate to the degassing of solutions of morphinum hydrochloricum, adrenalin and vitamin E dissolved in olive oil.  After being degassed these solutions can be sterilized at temperatures of 110 to 115 DEG C during a period of 15 minutes.
The intervention group will work with the study physiotherapist and perform a 10-20 minute progressive exercises twice per week. The intervention will include a series of exercises including dynamic balance, adaptation, cervical spine strength, cervical spine neuromotor control and divided attention exercises. Exercises will begin at a lower level and progress to increasingly difficult levels of each exercise type over the course of the intervention. Concussion education and injury identification will also be completed.
Participants received BL-B01D1, SI-B003 or BL-B01D1 + SI-B003 therapy in the first cycle (3 weeks). Participants who had a clinical benefit could receive additional cycles of additional treatment. Administration will be discontinued because of disease progression or intolerable toxicity or for other reasons.
The invention provides a novel treatment method, a novel traditional Chinese medicine formula and a novel traditional Chinese medicine dosage for male sexual dysfunction. Rejuvenation navel patch is composed of flos caryophyllata, lindera aggregata, rubus idaeus, a traditional Chinese medicine the inventor called Sheyingzi and centipedes. A traditional Chinese traditional medicine extraction process, alcohol extraction method, is employed to extract the active components. The active components are mixed with stearic acid and a medical transdermal agent uniformly to obtain a mixture. The mixture then is pressed to form the patch. The patch is fixed on navel of a patient with an external fixing band having an impermeable cushion, wherein the patch is quickly liquefied and then is absorbed under the effect of body temperature. The patch achieves excellent treatment effects since the patch is free of being metabolized and damaged in gastrointestinal tract and liver.
PROBLEM TO BE SOLVED: To obtain a bathing agent exhibiting excellent bathing effect and excellent in effects such as moisture-retaining effect, prevention of roughened skin and heat insulation by using a specific amino acid as an active ingredient. SOLUTION: This bathing agent contains a polyacidic amino acid as an active ingredient. Formulation amount of the polyacidic amino acid to the bathing agent is 0.01-30 wt.%. Polyglutamic acid or polyaspartic acid is preferably used as the polyacidic amino acid. The polyglutamic acid has preferably 3,000-500,000 molecular weight. A polyaspartic acid having 500-100,000 molecular weight is used as the polyaspartic acid. The bathing agent can be prepared in a dosage form of powder, granules, liquid or sold.
OBJECTIVE: This study aimed to assess the risks and benefits of reinitiating antiplatelet therapy after spontaneous intracerebral hemorrhage (ICH) through a systematic review and meta-analysis. The reinitiation of antiplatelet therapy is commonly used to reduce major vascular events in patients with occlusive vascular diseases, but its use in ICH patients may increase the risk of bleeding.
MATERIALS AND METHODS: A comprehensive search was conducted on databases including MEDLINE, Embase, Cochrane Library, clinicaltrials.gov, and the International Standard Randomized Controlled Trial Number Register (ISRCTN). Randomized controlled trials and cohort studies that investigated the use of reinitiation of antiplatelet therapy after hemorrhagic stroke were included. Data on ICH recurrence, major bleeding events, major occlusive cerebrovascular events, ischemic stroke, and all-cause mortality were extracted and analyzed using R software.
RESULTS: The study included a total of 10 studies with 6,340 participants. The control group consisted of 2,964 patients who did not receive antiplatelet therapy, while the study group included 1,285 patients who received antiplatelet therapy without restrictions on the specific drug type. The meta-analysis showed that antiplatelet therapy significantly reduced the risk of ICH recurrence (RR=0.72, 95% CI: 0.59, 0.87), had no significant impact on the risk of severe bleeding events (RR=0.93, 95% CI: 0.80, 1.08), significantly lowered the risk of major occlusive cerebrovascular events (RR=0.59, 95% CI: 0.46, 0.77), had no significant effect on the risk of ischemic stroke (RR=0.77, 95% CI: 0.53, 1.12), and did not significantly influence the risk of all-cause mortality (RR=0.75, 95% CI: 0.45, 1.15).
CONCLUSIONS: Based on the findings, reinitiating antiplatelet therapy after spontaneous ICH appears to be generally safe. However, the benefits in terms of reducing the risk of all-cause mortality are not evident and require confirmation through large-scale, long-term, prospective, randomized controlled trials.
The invention discloses a medicine for treating gastropathy and a preparation method of the medicine. The medicine comprises the following raw materials in parts by weight: 45-55 parts of Endoconcha Sepiae, 25-35 parts of Bulbus Fritillariae Thunbergii and 25-35 parts of Rhizoma Atractylodis Macrocephalae (parched with earth). The preparation method comprises the following steps: (1) screening raw herbal materials, cleaning, drying and pulverizing; and (2) sampling according to weight ratio, and mixing evenly to obtain the final product. The medicine has good treatment effects on gastric diseases such as chronic gastroenteritis, gastric erosion, gastric ulcer and gastrorrhagia. The preparation method is simple, and the medicine is low in cost, takes effect quickly, is good in curative effect and small in side effect, and is orally taken conveniently and quickly. In clinical treatment, 600 patients use the medicine, and total effective rate is 90%.
BACKGROUND: Since Imbach [1] first reported the use of high-dose intravenous immunoglobulin (IVIg) in the treatment of idiopathic thrombocytopenic purpura (ITP) in children, indications for IVIg therapy have been increaseing. At present, IVIg infusion has become an important means of clinical treatment. The phenomenon of anti-HBs and anti-HBc elevation caused by IVIg infusion in patients has been reported in journals, but similar reports in journals related to laboratory diagnosis are rare.
METHODS: We reported a case of a patient with immune thrombocytopenia (ITP) which interfered with hepatitis B virus (HBV) serological detection after receiving intravenous IVIg. We used chemiluminescence immunoassay to detect serological markers of HBV. IU/mL was used to represent the detection data of HBsAg and HBsAb and cutoff value was used to represent the detection HBeAg, HBeAb, and HbcAb.
RESULTS: The serological markers of HBV were all negative before IVIg infusion. One week after IVIG infusion, the item was tested again, and the results of HBsAb, HBeAb, and HBcAb were positive. As the time increased after infusion, HBsAb, HBeAb, and HBcAb in the patient gradually decreased.
CONCLUSIONS: After IVIg infusion, the sudden positive change of HBsAb, HBeAb, and HbcAb in the patient's body was not caused by HBV infection, but caused by the infusion of foreign antibody. This case study shows that physicians should be particularly careful when interpreting results in patients treated with intravenous IVIg involving viral hepatitis B.
BACKGROUND: The occurrence of multimorbidity and its impacts have differentially affected population subgroups. Evidence on its incidence has mainly come from high-income regions, with limited exploration of racial disparities. This study investigated the association between racial groups and the development of multimorbidity and chronic conditions in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil).
METHODS: Data from self-reported white, brown (pardos or mixed-race), and black participants at baseline of ELSA-Brasil (2008-2010) who were at risk for multimorbidity were analysed. The development of chronic conditions was assessed through in-person visits and self-reported diagnosis via telephone until the third follow-up visit (2017-2019). Multimorbidity was defined when, at the follow-up visit, the participant had two or more morbidities. Cumulative incidences, incidence rates, and adjusted incidence rate ratios (IRRs) were estimated using Poisson models.
RESULTS: Over an 8.3-year follow-up, compared to white participants: browns had a 27% greater incidence of hypertension and obesity; and blacks had a 62% and 45% greater incidence, respectively. Blacks also had 58% more diabetes. The cancer incidence was greater among whites. Multimorbidity affected 41% of the participants, with a crude incidence rate of 57.5 cases per 1000 person-years (ranging from 56.3 for whites to 63.9 for blacks). Adjusted estimates showed a 20% higher incidence of multimorbidity in black participants compared to white participants (IRR: 1.20; 95% CI: 1.05-1.38).
CONCLUSIONS: Significant racial disparities in the risk of chronic conditions and multimorbidity were observed. Many associations revealed a gradient increase in illness risk according to darker skin tones. Addressing fundamental causes such as racism and racial discrimination, alongside considering social determinants of health, is vital for comprehensive multimorbidity care. Intersectoral, equitable policies are essential for ensuring health rights for historically marginalized groups.
Resilient system performance in high-stakes settings, which includes the ability to monitor, respond, anticipate, and learn, can be enhanced for trainees through simulation of realistic scenarios enhanced by augmented reality. Active learning strategies can enhance simulation-based training, particularly the mental model articulation principle where students are prompted to anticipate what will happen next and the reflection principle where students self-assess their performance compared to a gold standard expert model. In this paper, we compared simulation-based training for trauma care with and without active learning strategies during pauses in the simulated action for progressively deteriorating patients. The training was conducted online and real-time without a facilitator, with 42 medical students viewing training materials and then immediately taking an online quiz for three types of trauma cases: hemorrhage, airway obstruction, and tension pneumothorax. Participants were randomly assigned to either the experimental or control condition in a between-subjects design. We compared performance in the control and experimental conditions based on: A) the proportion of cues correctly recognized, B) the proportion of accurate diagnoses, C) the proportion of appropriate treatment interventions, and D) verbal briefing quality on a 1-5 scale. We found that the training intervention increased recognition of subtle cues critical for accurate diagnosis and appropriate treatment interventions; the training did not improve the accuracy of diagnoses or the quality of the verbal briefing. We conclude that incorporating active learning strategies in simulation-based training improved foundational capabilities in detecting subtle cues and intervening to rescue deteriorating patients that can increase the readiness for trainees to contribute to resilient system performance in the high-stakes setting of emergency care in hospitals.
A shampoo formulation containing a washing agent, herb extracts, anti- dandruff agent, hair loss treatment agent and pH regulator  The viscous phase is prepared by mixing 150ml of washing agent with 15ml of pH regulator and rotary stirring for 30 minutes at 40 deg  C. The pH regulator is dosed in over 10 minutes. The aqueous phase is prepared in a similar manner by mixing 12.5 ml each of hair loss treatment agent and special active principles: arnica extract, herb bennet extract, birch extract, anti-dandruff agent in 295g water with 5g salt and 15ml sodium chloride (sic). The two phases are placed on a warmer at 40 deg  C for 30 minutes. The aqueous phase is added to the viscous phase while stirring. Oil of eucalyptus is added at 0.03- 0.05% and red coloring at 0.03-0.05% (3-5 drops). The shampoo is then packed. The anti- dandruff agent also serves as preservative.
A water-insoluble, hydrophilic, pressure-sensitive adhesive that has a number of unique characteristics including being elastomeric and ultraconformable comprises an irradiation cross-linked synthetic organic polymer having a three-dimensional matrix, and an adhesive plasticizer. Suitable polymers include polyvinyl alcohol, polyvinyl pyrrolidone, quaternised polyvinyl pyrrolidone, polyacrylic acid and methylvinyl ether/maleic anhydride copolymer. The plasticizer includes a substantially non-volatile elasticizer and may comprise, for example, polethylene glycol or sorbitol. The adhesive is useful either as a coating on a supporting web-like substrate or as a self- supporting layer. Also provided are various articles made using the adhesive such as a bandage or ostomy device, a method of making the adhesive, and methods of using the adhesive. In one embodiment, the adhesive is electroconductive, and is useful for attaching an electrically conductive member of an electrode to a selected surface such as mammalian tissue. Also provided is an electrode having a layer of this adhesive, and a method of adhering this electrode to mammalian tissue.